blinatumomab
amgen
['caveat', 'leusm']
#asco23 #leusm yaghmour: ino/blin (alliance) compares favorably to blin monotherapy in 1l (swog1318) with cr/cri 96% vs 66% (caveats apply of course). 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)